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EFFECTIVE COMPLIANCE MEANS IMPOSING INDIVIDUAL 
LIABILITY 
Reuben A. Guttman∗ 
Deputy Attorney General Sally Yates said it in a memo dated 
September 9, 2015, and her successor, Rod Rosenstein, said it in remarks 
dated October 6, 2017: corporations act through individuals, and 
compliance enforcement must necessarily account for holding individuals 
liable for the wrongs they orchestrate under cover of the corporate 
umbrella.1 
The logic is reasonable and necessary. We blame corporations for 
catastrophic environmental events2, misbranded drugs that cause injury, 
and financial products that destroy the life savings of those who have toiled 
for a living; yet at the helm of the corporations—guiding their path of 
impropriety—are people, many of whom who have benefited handsomely 
from the corporate misconduct that they have captained. Unfortunately, in 
comparison to the guilty pleas that are taken by corporations, which cannot 
be put behind bars, prosecutors—both criminal and civil—barely scratch 
the surface when it comes to pursuing the individual human culprits.  
This is not to say that there have been no criminal prosecutions of 
individuals for corporate crime. Insider trading cases are quite common, 
and when the wrongdoing has catastrophic consequences, as in Enron, 
Tyco, WorldCom, and the Madoff organization, prosecutors have put real 
people behind bars.3 
 
 ∗ Reuben A. Guttman is a partner at Guttman, Buschner & Brooks, PLLC and has represented 
whistleblowers in cases against the pharmaceutical industry which have returned more than $5 Billion to the 
Federal and State governments. He is an Adjunct Professor at Emory Law School and a Senior Fellow at the 
Center for Advocacy and Dispute Resolution. He is also a member of the Board of the American Constitution 
Society. He extends thanks to his colleagues Traci Buchner, Justin Brooks, Liz Shofner, Caroline Poplin, MD, 
Dan Guttman, Paul Zwier, Richard Harpootlian, the Honorable Nancy Gertner, and Joy Bernstein, who have 
been a constant sounding board for these issues. 
 1 See “Individual Accountability for Corporate Wrongdoing,”U.S. Department of Justice (September 9, 
2015) https://www.justice.gov/archives/dag/file/769036/download; Rod J. Rosenstein, Deputy Attorney 
General, Keynote Address at the NYU Program on Corporate Compliance & Enforcement (October 6, 2017) 
https://wp.nyu.edu/compliance_enforcement/2017/10/06/nyu-program-on-corporate-compliance-enforcement-
keynote-address-october-6-2017/. 
 2 “Deepwater Horizon,” U.S. Department of Justice: Environment and Natural Resources Division, 
https://www.justice.gov/enrd/deepwater-horizon.  
 3 See Aaron Smith, “Madoff Arrives at N.C. Prison”, CNN:Money (stating Bernie Madoff, release date 
November 14, 2139, is inmate 61727-054 at the Butner Medium Security Prison) (July 14, 2009 2:19 PM) 
(http://money.cnn.com/2009/07/14/news/economy/madoff_prison_transfer/; Marcia Heroux Pounds, “Dennis 
Kozlowski, former Tyco CEO who went to prison, back in M&A business”, Sun-Sentinel (stating Tyco CEO 
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There are, however, too many instances where individuals have put a 
corporation on a destructive tear, and still managed to elude personal 
liability. Considering that many of the large drug companies have either 
taken guilty pleas or paid fines to the government for conduct that has 
placed patients at risk by causing the consumption of powerful, 
unnecessary drugs, it is astounding that few, if any, pharmaceutical 
executives have been pursued criminally for conduct tantamount to 
battery.4 Imagine, for example, if an intruder broke into your house, opened 
your medicine cabinet, and loaded the cabinet with bottles of pills that were 
either not medically necessary—or worse—could cause physical injury or 
illness? How far removed is this from marketing schemes that cause 
doctors to write prescriptions based on misinformation, that cause 
dangerous products to be placed in medicine cabinets and ultimately 
consumed? Or what about the drug companies that funnel kickbacks to 
doctors disguised as “speaker fees” or “consulting agreements” while 
monitoring prescription data to confirm that the doctors are writing the 
“scripts” as directed.  
In 2012, Abbott Labs, one of the largest pharmaceutical companies in 
the world, plead guilty to illegally marketing the powerful drug, Depakote, 
which is a limited indication anti-epileptic. Among other things, Abbott 
marketed the drug to elderly patients in nursing homes for off-label 
purposes and for pediatric use, even though Depakote was not approved to 
treat anyone under the age of 18. After the entry of a guilty plea, the U.S. 
Attorney for the Western District of Virginia, Timothy Heaphy, noted in a 
Department of Justice press release that, “Abbott unlawfully targeted a 
vulnerable patient population, the elderly, through its off-label 
 
Dennis Kozlowski spent six and one half years in prison and was released in 2015) (Jan. 11, 2017 6:26 PM) 
http://www.sun-sentinel.com/business/fl-dennis-kozlowski-life-after-prison-20170111-story.html;”Bernie 
Ebbers’ wife files for divorce,” NewsOK (Worldcom CEO, Bernard J Ebbers, release date July 4, 2028, is 
inmate number 56022-054 at the FMC Forth Worth Federal Prison) (April 23, 2008 4:48 AM) 
http://newsok.com/article/3233823; Rufus-Jenny Triplett, “Prisonworld View-Corporate CEO Gets Skimmed 
Sentence,” Dawah Interational, LLC (stating Former Enron CEO, Jeffrey K Skilling, release date February 21, 
2019, is inmate number 29296-179 at the FPC Montgomery Federal Prison Camp) (May,15, 2015) 
http://prisonworldblogtalk.com/2015/05/15/prisonworld-view-corporate-ceo-gets-skimmed-sentence/.  
 4 See, e.g., “Criminal Resolution”, U.S. Department of Justice: Glaxosmithkline Settlement Fact Sheet, 
https://www.justice.gov/sites/default/files/usao-ma/legacy/2012/10/09/Settlement_Fact_Sheet.pdf ; “Pfizer to 
Pay $2.3 Billion for Fraudulent Marketing,” U.S. Department of Justice: Justice Department Announces 
Largest Health Care Fraud Settlement in its History, https://www.justice.gov/opa/pr/justice-department-
announces-largest-health-care-fraud-settlement-its-history; Megan Stride, “Wyeth Paying $491 M to End 
Criminal, Civil Rapamune Cases”, Law360, https://www.law360.com/articles/461203/wyeth-paying-491m-to-
end-criminal-civil-rapamune-cases 
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promotion.”5 Think hard about this statement; a company that holds itself 
out as a manufacturer of life-saving drugs was knowingly placing patients 
at risk for the purpose of making a buck.  
In 2013, Wyeth Pharmaceuticals agreed to pay $490.9 million in 
criminal and civil penalties for engaging in proscribed marketing practices 
regarding the prescription drug, Rapamune. Rapamune is an immuno-
suppressive drug—that is, it prevents the body’s immune system from 
rejecting a transplanted organ. At the time of the guilty plea, Wyeth had 
merged into Pfizer, and was no longer a standalone entity. Wyeth plead 
guilty to a criminal information, charging it with a misbranding violation 
under the Food, Drug, and Cosmetic Act. In characterizing the case, 
Antoinette V. Henry, Special Agent in Charge of the Metro-Washington 
field office of the FDA’s Office of Criminal Investigations noted, “Wyeth’s 
conduct put profits ahead of the health and safety of a vulnerable patient 
population dependent on life sustaining therapy.”6 Also in 2013, pharma-
giant GlaxoSmithKline plead guilty and paid $3 billion to the government 
in order to resolve fraud allegations and the failure to report safety data. As 
part of a global settlement, the company also settled a series of civil claims 
under the False Claims Act, stemming from marketing derelictions 
including kickbacks.  
Time and time again, large pharmaceutical companies have engaged in 
conduct that placed patients at risk, and, at times, caused real harm, yet, 
virtually no individual has been prosecuted or put behind bars.7 The idea 
that misrepresentations, kickbacks, and assorted fraudulent schemes can be 
employed to cause patients to put drugs in their bodies at personal peril 
without anyone going to prison is stunning. Our jails have no shortage of 
inmates sentenced to long terms for selling illegal drugs and/or engaging in 
various batteries. Yet, when white collar executives engage in schemes to 
drive revenue by causing the consumption of extra drugs, or the use of 
drugs for improper purposes, individual liability is rare.  
 
 5 See “Abbott Laboratories Sentenced for Misbranding Drug”, U.S. Department of Justice (October 2, 
2012) https://www.justice.gov/opa/pr/abbott-laboratories-sentenced-misbranding-drug. 
 6 See “Wyeth Pharmaceuticals Agrees To Pay $490.0 Million For Marketing The Prescription Drug 
Rapamune For Unapproved Uses”, U.S. Department of Justice (July 30, 2012) https://www.justice.gov/usao-
wdok/pr/wyeth-pharmaceuticals-agrees-pay-4909-million-marketing-prescription-drug-rapamune. 
 7 See Erica Goode, “3 Schizophrenia Drugs May Raise Diabetes Risk, Study Says”, The New York 
Times (August 25, 2003) https://mobile.nytimes.com/2003/08/25/us/3-schizophrenia-drugs-may-raise-
diabetes-risk-study-says.html. 
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Consider that this nation is immersed in battling what the press now 
calls the “opioid crisis”8 or the “opioid epidemic.” 9 This crisis reared its 
head at least a decade ago when the U.S. Attorney in the Western District 
of Virginia prosecuted the drug manufacturer Purdue Pharma, and three 
corporate executives for illegally marketing the drug Oxycontin. On July 
23, 2007, the United States District Court for the Western District of 
Virginia (James P. Jones, Judge) issued an Opinion and Order approving a 
criminal plea agreement and summarizing its provisions. Among other 
misdeeds, during a six-year period, “certain Purdue supervisors and 
employees with the intent to defraud or mislead, marketed and promoted 
OxyContin as less addictive, less subject to abuse and diversion, and less 
likely to cause tolerance and withdrawal than any other pain medications.” 
Among an array of specific derelictions, Purdue representatives “told 
certain health care providers that Oxycontin did not cause a ‘buzz’ or 
euphoria, caused less euphoria, had less addiction potential, had less abuse 
potential, was less likely to be diverted than immediate-release opioids, and 
could be used to ‘weed out’ addicts and drug seekers.”10 The court’s 
opinion noted that “Purdue has agreed that these facts are true, and that the 
individual defendants, while they do not agree that they had knowledge of 
these things, have agreed that the Court may accept these facts in support 
of their guilty pleas.” The plea agreement—accepted by the Court—called 
for Purdue to pay approximately $600 million to resolve civil and criminal 
claims. It also provided that no individual defendant would be incarcerated. 
In the absence of record proof of their culpability, the Court was left with 
no choice but to accept the agreement as to no prison time for individuals. 
Noting what we now know about the opioid problem, the Court made this 
ominous point: 
I would have preferred that the plea agreements had allocated some 
amount of the money for the education of those at risk from the 
improper use of prescription drugs, and the treatment of those who 
have succumbed to such use. Prescription drug abuse is rampant in 
all areas of our country, particularly among the young people, 
causing untold misery and harm. The White House drug policy office 
estimates that such abuse rose seventeen percent from 2001 to 2005. 
That office reports that currently there are more new abusers of 
 
 8 Opiod Crisis Fast Facts, CNN: Health, (March 2, 2018 9:25 AM) https://www.cnn.com/2017/09/18/ 
health/opioid-crisis-fast-facts/index.html 
 9 M. Scott Brauer, “Inside a Killer Drug Epidemic: A Look at America’s Opioid Crisis, (Jan. 6, 2017) 
(according to the New York Times, “the opioid epidemic killed more than 33,000 people in 2015) 
https://www.nytimes.com/2017/01/06/us/opioid-crisis-epidemic.html.  
 10 United States v. Purdue Frederick Co., 963 F.Supp.2d 561 (W.D.Va. 2013).  
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prescription drugs than users of any illicit drugs. As recently 
reported, “Young people mistakenly believe that prescription drugs 
are safer than street drugs. . . but accidental prescription drug deaths 
are rising and students who abuse pills are more likely to drive fast, 
binge-drink and engage in other dangerous behaviors.” Carla K. 
Johnson, Arrest Puts Spotlight on Prescription Drug Abuse, The 
Roanoke Times, July 6, 2007, at 4A. It has been estimated that there 
are more than 6.4 million prescription drug abusers in the United 
States.11 
Fast-forward eleven years, and the opioid crisis—which commenced 
with pharmaceutical companies manufacturing and marketing opioids well 
beyond their legitimate demand—and we have a nation now addicted to 
drugs, with additional supplies flowing from Mexico and China. The origin 
of this crisis is not just the drug companies; it starts with the individuals 
who ran the drug companies, placing revenue generation ahead of medical 
need—perhaps because bonus structures and stock options made it 
personally advantageous.12 
Today, legislators on Capitol Hill grouse about the cost of our 
healthcare system and debate what level of benefits should be reduced. Yet, 
few, if any, lawmakers focus on what should be a front-end question: how 
much money is being wasted through fraud and abuse? Few, if any 
lawmakers are even contemplating a second question: how much money is 
spent to treat injuries and illnesses attributable to drugs that should never 
have been taken? And few, if any, have contemplated how to change 
behavior by holding individuals accountable. And of course, few, if any, 
legislators have contemplated making drug companies pay for wide 
dissemination of honest information about their products as one Federal 
Judge in the Western District of Virginia contemplated over a decade ago.  
At the end of the day, if there is a perception that only a legal fiction 
will be caught holding the bag (albeit a fiction impossible to imprison), 
corporations—and those individuals that control their conduct—will view 
civil and even criminal sanctions as simply the price for a license to break 
the law. And to company insiders—that is to say, the shareholders, officers 
 
 11 Id.  
 12 See Reuters, U.S. Senator Sanders Introducing Bill Targeting Opioid Manufacturers, VOA: USA, 
(April 17, 2018 10:24 AM) (stating the idea of imposing harsher criminal penalties on drug company 
executives has been championed by Vermont Senator Bernie Sanders who has proposed the Opioid Crisis 
Accountability Act of 2018) https://www.voanews.com/a/us-senator-sanders-bill-opioids-manufacturers/ 
4351732.html 
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and Directors—paying this fee for the license to break the law may be 
worth it if the analysis was simply a matter of dollars and cents.  
In 2012, when Pfizer paid $2.3 billion to settle unlawful marketing 
claims involving a number of its products, it was a small price to pay for 
the right to engage in a history of conduct that generated a revenue stream 
in excess of $100 billion.13 Moreover, it was a small price to pay for the 
right to poison the market for honest medical information and thus establish 
a standard of care that would generate a revenue stream in the years to 
come. Put simply, when companies engage in pervasive misbranding of 
their products over a period of years, they disseminate misinformation that 
then becomes the standard of care. While that standard may not be 
evidence based, it is still hard to undo. Hence, paying a mere dollar fine 
will not reset or correct the market for honest medical information; and so 
manufactures get the continued benefit of a standard of care which may 
encourage use of a product even though it is potentially harmful or not 
otherwise medically necessary. 
It is not just a problem endemic to the pharmaceutical industry. An 
array of corporations routinely game the system seemingly calculating the 
penalties for non-compliance. Publicly traded big box stores routinely 
pollute our navigable waterways with runoffs from parking lots that 
aggregate toxic hydrocarbons from leaky vehicles. Similarly, 
manufacturing plants have created a legacy—and continue to do so—of 
groundwater contamination that will for centuries prevent the safe 
enjoyment of our aquifers and tributaries. They do so because the cost of 
preventing the harm may well exceed the fine. 
The externalities of corporate greed are not only imposed on 
consumers. Labor lawyer, Jon Karmel, in his recent book, Dying to Work,14 
raises awareness of unsafe working conditions that have resulted in death 
and/or injury to workers. Karmel traveled the country to interview victims 
and their families and his book highlights how corporations have simply 
not placed a premium on protecting their workers from harm. 
Unfortunately, our laws make it too easy for employers to game out the 
penalty for unsafe workplaces. Workers compensation systems designed to 
provide injured workers with quick relief also cap liability by preventing 
direct causes of action for significant actual and punitive damages. There is 
 
 13 See Gardiner Harris, “Pfizer Pays $2.3 Billion to Settle Marketing Case”, The New York Times 
(September 2, 2009) https://www.nytimes.com/2009/09/03/business/03health.html. 
 14 Karmel, Jon, Dying to Work, Cornell University Press (2017)  
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no shortage of reports of coal miners toiling in unsafe mines replete with 
regulatory derelictions, who have lost life and/or limb in pursuit of 
company profit.15 Yet, compensation systems cap the employer’s economic 
exposure and—again—at the end of the day, few, if any, individuals are 
held personally accountable.16 For the corporation, the fix or preventative 
measures are often considered more expensive than the penalty. 
Over the past year, the nation has come to realize what many have 
known as true for some time; that discrimination based on class, race, 
gender, and national origin festers in our workplaces. There may be few, if 
any, visible cross burnings in this century, but the internet and cyberspace 
are overflowing with evidence that the most vulgar forms of racism and 
gender discrimination are thriving even in the 21st century. Perhaps, some 
had thought, that the civil rights legislation of the 1960s struck a blow to 
discrimination, causing its demise. Although we sing the praises of this 
legislation, it too caps liability and limits the rights of the aggrieved. 
Consider Title VII of the 1964 civil rights act17—that statute requires that 
claims of discrimination be brought within six months.18 Punitive damages 
are capped, and the courts have impeded plaintiffs from seeking redress on 
a class basis for wrongful conduct.19 Other than damage to brand and 
reputation, employers can easily calculate the fee for the license to 
discriminate. Before the #MeToo movement, which now seemingly causes 
consumers to factor in a company’s compliance with laws proscribing 
discrimination in evaluating the integrity of a brand, derelictions of 
employment laws had less severe consequences for corporate wrongdoers. 
 
 15 See, e.g., Dana Ford, “Don Blankenship, ex-Massey Energy CEO, sentenced to a year in prison,” 
CNN, (April 6, 2016 11:29 PM) (explaining it was the explosion at Massey Energy’s Upper Big Branch mine 
which killed 29 people. Massey CEO Don Blankenship was ultimately convicted of a misdemeanor with 
regard to the skirting of safety regulations. He served one year in prison and is now a candidate for the United 
States Senate in West Virginia) https://www.cnn.com/2016/04/06/us/former-massey-energy-ceo-don-
blankenship-sentenced/index.html; Nicole Gaudiano, “Don Blankenship, convicted ex-Massey CEO now 
Senate candidate, calls for more mine safety,” USAToday: OnPolitics, (April 4, 2018 6:43 PM) 
https://www.usatoday.com/story/news/politics/onpolitics/2018/04/04/don-blankenship-convicted-massey-ceo-
senate-candidate/487230002/.  
 16 See “Dying to Work: Death and Injury in the American Workplace”, Cornell University Press 
(December 2017).  
 17 42 U.S.C § 2000e (1964). 
 18 Dov Ohrenstein, “Limitation Periods–What’s the Limit,” Healys LLP, http://www.radcliffechambers. 
com/wp-content/uploads/2010/02/Limitation_seminar_-_Dov_Ohrenstein.pdf (Explaining in comparison to 
claims for contracts and most torts, six months is a very limited statute of limitations. Undoubtedly many 
claims die on the vine because they were not brought in time)  
 19 See infra note 18. 
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For years, Wal-Mart battled claims of pervasive gender discrimination 
without any significant impact on its brand. 20 
Against this backdrop, the regulators and those enforcing compliance 
routinely tout million, multi-million, and even billion-dollar settlements as 
evidence of efforts that change corporate behavior. But do these settlements 
really change behavior? The answer is no. If our laws are structured to 
allow corporate defendants to game out the penalty, corporate insiders will 
gauge the cost of noncompliance as the cost of doing business. Penalties 
that appear to be massive may be minimal when compared to the profits the 
corporation secured through wrongful conduct. If corporations can game 
out the price of non-compliance and individual wrongdoers can hide behind 
the corporate cloak and continue to collect bonuses based on unlawful 
corporate conduct, business will continue as usual. And this is the lesson 
for both regulators and lawmakers.  
 
 
 20 Wal-Mart Stores, Inc. v. Dukes, et al., 564 U.S. 338 (2011) (explaining the case is one of several 
cases impacting the ability to certify class action discrimination cases).  
